ResearchStructural repertoire of HCV broadly neutralizing antibodies targeting the E2 front layer supersite
ResearchAntigenicity of key hepatitis C virus E1E2 glycoprotein neutralizing sites is genotype independent
ResearchHIV causes global B-cell dysregulation and restricts HBV-specific B-cell development in an incident HBV cohort
ResearchGlycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity
ResearchNeutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection
ResearchConvergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance
ResearchRecombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 alone
ResearchImmunogenicity and Reactogenicity Following 2- and 3-Dose SARS-CoV-2 Vaccination in Persons With HIV
ResearchSerum neutralization activity declines but memory B cells persist after cure of chronic hepatitis C
ResearchComputational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals
ResearchRepeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency